A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Running, not enrolling

Conditions studied: Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma

In brief

TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participants meet the eligibility criteria for these parameters and could potentially be enrolled in a TScan clinical study.

Key facts

Study ID

NCT05812027

Run by

TScan Therapeutics, Inc.

People needed

1150

Starts

2023-06-26

Expected to finish

2027-01-14

Last updated by the study team

2025-11-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Willing and able to provide written informed consent.
• Male or female aged ≥18 years at the time of signing the informed consent.
• Have one of the following histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumor for which the Sponsor has an associated clinical study:
• Head and neck cancer
• Cervical cancer
• Non-small cell lung cancer
• HPV positive anogenital cancers
• Sarcoma
• Other cancers with a reasonable likelihood of expressing 1 or more antigens included in a TScan clinical trial, following approval by the TScan Medical Monitor or their delegate.
• Willing to provide a buccal swab for HLA testing
• Willing to provide a saliva sample to use as a normal control for the LOH assay
• Have access to an adequate FFPE tumor block that is <8 months old or is willing to provide a fresh core-needle biopsy from a location deemed safe by the treating medical team.

You may not qualify if…

• Participants undergoing anticancer therapy with curative intent such as tumor surgical resection with or without neoadjuvant/adjuvant therapy, or definitive chemoradiation, unless they have locoregionally advanced disease and are expected to have a high risk of relapse after their curative intent therapy as determined by the treating investigator.

Where it is running

• HonorHealth Research and Innovation Institute — Scottsdale, Arizona, United States
• University of California San Diego — San Diego, California, United States
• Yale Cancer Center — New Haven, Connecticut, United States
• Memorial Healthcare System — Hollywood, Florida, United States
• University of Miami, Sylvester Comprehensive Cancer Center — Miami, Florida, United States
• Orlando Health — Orlando, Florida, United States
• University of South Florida — Tampa, Florida, United States
• University of Chicago — Chicago, Illinois, United States
• Norton Cancer Institute — Louisville, Kentucky, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• University of Minnesota, Masonic Cancer Center — Minneapolis, Minnesota, United States
• Columbia University Herbert Irving Comprehensive Cancer Center — New York, New York, United States
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States
• Oncology Hematology Care — Cincinnati, Ohio, United States
• The Cleveland Clinic — Cleveland, Ohio, United States
• OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
• Providence Cancer Institute Franz Clinic — Portland, Oregon, United States
• Allegheny Hospitals Network — Pittsburgh, Pennsylvania, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• Baylor College of Medicine — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.